Lee PH - Search Results

1

Using a Polygenic Risk Score to Improve the Risk Prediction of Non-Small Cell Lung Cancer in Taiwan.

Lee PH, Chen IC, Chen YM, Hsiao TH, Tseng JS, Huang YH, Hsu KH, Lin H, Yang TY, Shao YJ. Lee PH, et al. JCO Precis Oncol. 2024 Oct;8:e2400236. doi: 10.1200/PO.24.00236. Epub 2024 Oct 2. JCO Precis Oncol. 2024. PMID: 39348659

2

Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors.

Lee PH, Yang TY, Chen KC, Huang YH, Tseng JS, Hsu KH, Wu YC, Liu KJ, Chang GC. Lee PH, et al. Sci Rep. 2021 Apr 30;11(1):9381. doi: 10.1038/s41598-021-89043-4. Sci Rep. 2021. PMID: 33931705 Free PMC article.

3

Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non-small cell lung cancer patients.

Lee PH, Chen KC, Hsu KH, Huang YH, Tseng JS, Yang TY, Chang GC. Lee PH, et al. Anticancer Drugs. 2021 Nov 1;32(10):1099-1104. doi: 10.1097/CAD.0000000000001107. Anticancer Drugs. 2021. PMID: 34232936

4

Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation: A single center cohort (STROBE-compliant).

Wu JJ, Lee PH, Zheng ZR, Huang YH, Tseng JS, Hsu KH, Yang TY, Yu SL, Chen KC, Chang GC. Wu JJ, et al. Among authors: lee ph. Medicine (Baltimore). 2022 Jun 17;101(24):e29381. doi: 10.1097/MD.0000000000029381. Medicine (Baltimore). 2022. PMID: 35713442 Free PMC article.

5

Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma.

Lee PH, Huang YH, Lin H, Hsu KH, Chen KC, Tseng JS, Chang GC, Yang TY. Lee PH, et al. Medicina (Kaunas). 2022 Jul 8;58(7):908. doi: 10.3390/medicina58070908. Medicina (Kaunas). 2022. PMID: 35888627 Free PMC article.

6

Various impacts of driver mutations on the PD-L1 expression of NSCLC.

Chu CH, Huang YH, Lee PH, Hsu KH, Chen KC, Su KY, Yu SL, Tseng JS, Yang TY, Chang GC. Chu CH, et al. Among authors: lee ph. PLoS One. 2022 Aug 18;17(8):e0273207. doi: 10.1371/journal.pone.0273207. eCollection 2022. PLoS One. 2022. PMID: 35980949 Free PMC article.

7

Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment.

Lee PH, Huang YH, Hsu YW, Chen KC, Hsu KH, Lin H, Lee TY, Tseng JS, Chang GC, Yang TY. Lee PH, et al. Among authors: lee ty. J Clin Med. 2022 Dec 28;12(1):231. doi: 10.3390/jcm12010231. J Clin Med. 2022. PMID: 36615034 Free PMC article.

8

Adjuvant chemotherapy compared with observation in patients with T2aN0 stage IB lung adenocarcinoma.

Lee PH, Chiang CJ, Tseng JS, Zheng ZR, Chen KC, Chu CH, Huang YH, Hsu KH, Lee WC, Yang TY, Liu TW, Hsia JY, Chang GC. Lee PH, et al. Among authors: lee wc. Front Oncol. 2023 Feb 28;13:1096683. doi: 10.3389/fonc.2023.1096683. eCollection 2023. Front Oncol. 2023. PMID: 36925928 Free PMC article.

9

Benefits of NGS in Advanced Lung Adenocarcinoma Vary by Populations and Timing of Examination.

Lee PH, Ou WF, Huang YH, Hsu KH, Tseng JS, Chang GC, Yang TY. Lee PH, et al. Int J Mol Sci. 2024 Jun 25;25(13):6949. doi: 10.3390/ijms25136949. Int J Mol Sci. 2024. PMID: 39000058 Free PMC article.

10

Real-world clinical efficacy of bevacizumab biosimilar in patients with advanced non-small-cell lung cancer.

Ou WF, Hsu KH, Tseng JS, Lee PH, Chen KC, Huang YH, Chang GC, Yang TY. Ou WF, et al. Among authors: lee ph. Ther Adv Med Oncol. 2024 Oct 17;16:17588359241290718. doi: 10.1177/17588359241290718. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39483140 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,163 results

Search Page

Filters